Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence
Annals of Neurology · 2026-01 · 99 (1) · 248-260
DOI: 10.1002/ana.78033 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Neurology, online erschienen am 08.09.2025. Verfasst von Gabriel Cerono und 3 weiteren Autor:innen. Beteiligte Einrichtung: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Rituximab, Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, Unrestricted departmental funds.
Abstract (Originalsprache)
Objective
The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS).
Methods
Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from 5 other UC Medical Centers were analyzed. After applying exclusion criteria and propensity score matching based on disease characteristics, demographics, and socioeconomic factors, we compared UCSF patients receiving ocrelizumab (n = 542) and rituximab (n = 271)and validated in the UC‐wide MS population (n = 486 and n = 162 patients, respectively). The primary outcome was an all‐cause hospitalization rate; secondary outcomes included hypogammaglobulinemia development and infection incidence.
Results
Rituximab showed higher all‐cause hospitalization rates compared to ocrelizumab in both UCSF (incidence rate ratio [IRR] = 2.29, 95% confidence interval [CI] = 1.37–3.82, p = 0.001) and UC‐wide cohorts (IRR = 4.54, 95% CI = 4.30–7.61, p < 0.001). Cumulative hazard ratios (HRs) were similarly elevated with rituximab at UCSF (HR = 2.27, 95% CI = 1.37–3.75, p = 0.001) and UC‐wide (HR = 4.01, 95% CI = 2.25–6.32, p < 0.001). The risk of developing hypogammaglobulinemia was higher with rituximab at both UCSF (HR = 2.72, 95% CI = 1.18–6.29, p = 0.003) and UC‐wide (HR = 4.79, 95% CI = 2.04–11.25, p < 0.001).
Interpretation
A more favorable safety profile was observed for ocrelizumab, with lower rates of hospitalization and hypogammaglobulinemia across 2 independent cohorts. These findings may help guide treatment strategies in persons with MS. ANN NEUROL 2026;99:248–260
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA.
ORCID-Profile: Bruce A C Cree, Stephen L Hauser, Sergio E Baranzini
Förderung
- NINDS NIH HHS
- Unrestricted departmental funds
Zitieren
APA
Cerono, G., Cree, B. A. C., Hauser, S. L., & Baranzini, S. E. (2026). Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence. Annals of Neurology, 99(1), 248-260. https://doi.org/10.1002/ana.78033
Vancouver
Cerono G, Cree BAC, Hauser SL, Baranzini SE. Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence. Annals of Neurology. 2026;99(1):248-260. doi:10.1002/ana.78033
BibTeX
@article{Cerono2026,
author = {Cerono, Gabriel and Cree, Bruce A C and Hauser, Stephen L and Baranzini, Sergio E},
title = {Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence},
journal = {Annals of Neurology},
year = {2026},
volume = {99},
number = {1},
pages = {248--260},
doi = {10.1002/ana.78033}
}
EUVIMED